Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06897943

Epidemiology of Gonococcal Arthritis (EpGAr)

The aim of this retrospective observational study was to describe the epidemiology of Neisseria gonorrhoeae septic arthritis over the last 10 years at Brest and Rennes university hospitals. The main question is whether there are any risk factors based on the epidemiological and clinical data on these cases. The second objective is to characterize the gonococcal strains isolated in order to determine whether there is a common clone, a virulence factor or specific resistance genes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gonococcal (GC) Infection Arthritis Arthritis, Infectious Bacterial Infections Bacterial Infections and Mycoses Communicable Diseases Genital Diseases Gonorrhea Gram-Negative Bacterial Infections Infections Joint Diseases Musculoskeletal Diseases Neisseriaceae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial Urogenital Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Rennes University Hospital, Rennes, Brittany Region, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 2014 and 2024.

Exclusion criteria

  • Patients with Neisseria gonorrhoeae-negative joint sample (from enrichment vial or native sample).
  • Patients who have expressed opposition to inclusion in the study.
  • Patients under legal protection (guardianship, curatorship, etc.).

Treatment and study plan

Primary outcomes

  1. Age

    Time frame: 10 years

    years

  2. Date of sampling

    Time frame: 10 years

    DD/MM/YYYY

  3. Type of sample

    Time frame: 10 years

    joint fluid or joint fluid on blood culture bottle

  4. Rate of white blood cells

    Time frame: 10 years

    quantification of white blood cells /mm3

  5. Sexually transmitted infection

    Time frame: 10 years

    associated or not, if associated, name of STI and localization

  6. Men who have sex with men

    Time frame: 10 years

    yes or no

  7. HIV pre-exposure prophylaxis (PreP)

    Time frame: 10 years

    yes or no

  8. Comorbidities

    Time frame: 10 years

    any history mentioned in the medical file, such as fracture, illness, treatment, chronic alcoholism, cancer, diabetes, etc.

  9. Imaging

    Time frame: 10 years

    medical conclusion of the ultrasound or radiology performed

  10. Blood cultures (peripheral blood)

    Time frame: 10 years

    positive or negative

  11. Time to diagnosis

    Time frame: 10 years

    in days (between onset of symptoms and antibiotics)

  12. Treatments implemented

    Time frame: 10 years

    name of the probabilistic treatment (antibiotic) and after identification or antibiogram

  13. Antibiotic sensitivity profile

    Time frame: 10 years

    Susceptibility or resistance according to SIR methodology and, if achieved: minimum inhibitory concentrations of antibiotics tested on the strain in mg/L

  14. Surgery

    Time frame: 10 years

    yes or not

  15. Evolution

    Time frame: 10 years

    recovery or relapse

  16. Rate of neutrophils

    Time frame: 10 years

    proportion of neutrophils in %.

  17. Rate of CRP (C-reactive protein)

    Time frame: 10 years

    in mg/L

Secondary outcomes

  1. Molecular typing: clone

    Time frame: 10 years

    performed on strains sent to the Centre National de Référence des IST - APHP

  2. Molecular typing: virulence factors

    Time frame: 10 years

    performed on strains sent to the Centre National de Référence des IST - APHP

  3. Molecular typing: resistance genes

    Time frame: 10 years

    performed on strains sent to the Centre National de Référence des IST - APHP

Study contacts

Contact information is provided by the study sponsor or research team.

Geneviève HERY-ARNAUD

CONTACT

[email protected]

0298145107 ext. +33

Valentin LEMOINE

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Epidemiology of Gonococcal Arthritis

Acronym: EpGAr

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 27, 2025
Registry last updated
Mar 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.